These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 33608920)

  • 1. Clinical phenotypes and therapeutic responses in cutaneous-predominant sarcoidosis: 6-year experience in a tertiary referral service.
    Paolino A; Galloway J; Birring S; Brex P; Larkin G; Patel A; Sado D; Murgatroyd F; Walsh S
    Clin Exp Dermatol; 2021 Aug; 46(6):1038-1045. PubMed ID: 33608920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Methotrexate for the treatment of patients with chronic cutaneous sarcoidosis: 4 cases].
    Gary A; Modeste AB; Richard C; Jubert C; Majour F; Nouvet G; Remond B; Joly P
    Ann Dermatol Venereol; 2005; 132(8-9 Pt 1):659-62. PubMed ID: 16230915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Sarcoidosis.
    Raghu G; Berman JS; Govender P
    Am J Respir Crit Care Med; 2018 Mar; 197(6):P9-P10. PubMed ID: 29543101
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and Tolerance of Anti-Tumor Necrosis Factor α Agents in Cutaneous Sarcoidosis: A French Study of 46 Cases.
    Heidelberger V; Ingen-Housz-Oro S; Marquet A; Mahevas M; Bessis D; Bouillet L; Caux F; Chapelon-Abric C; Debarbieux S; Delaporte E; Duval-Modeste AB; Fain O; Joly P; Marchand-Adam S; Monfort JB; Noël N; Passeron T; Ruivard M; Sarrot-Reynauld F; Verrot D; Bouvry D; Fardet L; Chosidow O; Sève P; Valeyre D
    JAMA Dermatol; 2017 Jul; 153(7):681-685. PubMed ID: 28564695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mycophenolate mofetil may serve as a steroid-sparing agent for sarcoidosis.
    Kouba DJ; Mimouni D; Rencic A; Nousari HC
    Br J Dermatol; 2003 Jan; 148(1):147-8. PubMed ID: 12534610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of neurosarcoidosis: A comparative study of methotrexate and mycophenolate mofetil.
    Bitoun S; Bouvry D; Borie R; Mahevas M; Sacre K; Haroche J; Psimaras D; Pottier C; Mathian A; Hie M; Boutin DL; Papo T; Godeau B; Valeyre D; Nunes H; Amoura Z; Cohen Aubart F
    Neurology; 2016 Dec; 87(24):2517-2521. PubMed ID: 27856779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxychloroquine Therapy in Sarcoidosis-Associated Uveitis.
    Bert A; El Jammal T; Kodjikian L; Gerfaud-Valentin M; Jamilloux Y; Seve P
    Ocul Immunol Inflamm; 2024 Feb; 32(2):154-160. PubMed ID: 36749910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cutaneous sarcoidosis: clinico-epidemiological profile of 72 patients at a tertiary hospital in São Paulo, Brazil.
    Torquato MF; Costa MKSD; Nico MMS
    An Bras Dermatol; 2020; 95(1):57-62. PubMed ID: 31889592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mycophenolate mofetil, azathioprine and methotrexate usage in paediatric anti-NMDAR encephalitis: A systematic literature review.
    Nosadini M; Mohammad SS; Toldo I; Sartori S; Dale RC
    Eur J Paediatr Neurol; 2019 Jan; 23(1):7-18. PubMed ID: 30318435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous sarcoidosis simulating porokeratosis of Mibelli.
    Elfatoiki FZ; Soussi W; Chiheb S; Jabri L; Benchikhi H
    Pan Afr Med J; 2015; 20():195. PubMed ID: 26113926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sarcoidal anemia and leukopenia treated with methotrexate and mycophenolate mofetil.
    Kalajian AH; Van Meter JR; Callen JP
    Arch Dermatol; 2009 Aug; 145(8):905-9. PubMed ID: 19687421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Mycophenolate mofetil in refractory Crohn's disease after failure of treatments by azathioprine or methotrexate].
    Hafraoui S; Dewit O; Marteau P; Cosnes J; Colombel JF; Modigliani R; Cortot A; Lémann M
    Gastroenterol Clin Biol; 2002 Jan; 26(1):17-22. PubMed ID: 11938035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous sarcoidosis therapy updated.
    Badgwell C; Rosen T
    J Am Acad Dermatol; 2007 Jan; 56(1):69-83. PubMed ID: 17190623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors Associated With Clinical Remission of Skin Disease in Dermatomyositis.
    Wolstencroft PW; Chung L; Li S; Casciola-Rosen L; Fiorentino DF
    JAMA Dermatol; 2018 Jan; 154(1):44-51. PubMed ID: 29114741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Which first-line treatment for cutaneous sarcoidosis? A retrospective study of 120 patients.
    Cohen E; Lheure C; Ingen-Housz-Oro S; Hotz C; Bettuzzi T; Chasset F; Descamps V; Deschamps L; Mahevas M; Terrier B; Sohier P; Guegan S; Kramkimel N; Darbord D; Chanal J; Oulès B; Aractingi S; Seta V; Dupin N
    Eur J Dermatol; 2023 Dec; 33(6):680-685. PubMed ID: 38465550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mycophenolate mofetil as an alternative treatment in sarcoidosis.
    Papiris S; Stagaki E; Papadaki G; Kolilekas L; Korbila I; Apollonatou V; Kallieri M; Gialafos H; Chatziioannou S; Papaioannou AI; Manali ED
    Pulm Pharmacol Ther; 2019 Oct; 58():101840. PubMed ID: 31518648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific cutaneous lesions in patients with systemic sarcoidosis: relationship to severity and chronicity of disease.
    Marcoval J; Mañá J; Rubio M
    Clin Exp Dermatol; 2011 Oct; 36(7):739-44. PubMed ID: 21790725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unusual manifestation of cutaneous sarcoidosis: a case report of morpheaform sarcoidosis.
    Vasaghi A; Kalafi A
    Acta Med Iran; 2012; 50(9):648-51. PubMed ID: 23165817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful steroid-sparing treatment of renal limited sarcoidosis with mycophenolate mofetil.
    Moudgil A; Przygodzki RM; Kher KK
    Pediatr Nephrol; 2006 Feb; 21(2):281-5. PubMed ID: 16362392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skin manifestations of sarcoidosis.
    Mañá J; Marcoval J
    Presse Med; 2012 Jun; 41(6 Pt 2):e355-74. PubMed ID: 22579238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.